SMA Neurologists News and Resources
Neurology Info 1
Design settings and even apply custom CSS to this text in the module Advanced settings.
Neurology Info 2
Design settings and even apply custom CSS to this text in the module Advanced settings.
Neurology Info 3
Design settings and even apply custom CSS to this text in the module Advanced settings.
Featured Neurologists Articles on HCP
A Physical Therapist’s Perspective On a Treatment for SMA in Patients 2 Months and Older Sponsored Post
As key team members in the management of spinal muscular atrophy (SMA),1physical therapists need to understand how disease-modifying therapies may impact patients with SMA and how to best assess these patients over time. Evrysdi (risdiplam) is a disease-modifying...
New Quality of Life Survey Aims to Help Inform SMA Community Needs
BioNews Insights is launching a new survey, in collaboration with SMA News Today, with the goal of understanding how different aspects of this disease affect an individual’s quality of life. The survey, which is expected to take about 15 minutes to complete,...
A Physical Therapist’s Perspective On a Treatment for SMA in Patients 2 Months and Older Sponsored Post
As key team members in the management of spinal muscular atrophy (SMA),1physical therapists need to understand how disease-modifying therapies may impact patients with SMA and how to best assess these patients over time. Evrysdi (risdiplam) is a disease-modifying...
New Data-sharing Program Aims to Speed Innovation in Rare Diseases
A new U.S. initiative called Rare Disease Cures Accelerator–Data and Analytics Platform — dubbed RDCA–DAP — aims to accelerate treatment innovation across rare diseases by sharing existing patient data and promoting the standardization of new data collection. Launched...
Pre-symptomatic Infants Retain Swallowing Ability in Evrysdi Trial
After being treated with Evrysdi (risdiplam) for at least a year, pre-symptomatic infants with spinal muscular atrophy (SMA) have retained the ability to swallow, and most have been able to stand and walk within developmentally normal windows. That’s according...
Spinraza RESPOND Trial Enrolling Children Not Helped by Zolgensma
Biogen is continuing to actively recruit patients for its Phase 4 RESPOND trial, which is evaluating the benefits of Spinraza (nusinersen) in infants and children with spinal muscular atrophy (SMA) who responded poorly to the gene therapy Zolgensma. Participants are...
Latest Posts from SMA News Today
Recent SMA Neurologist News
RSS feed from SMA News Today
SMA Forums -- Neurologist
RSS feed from SMA News Today
